Rime Bioinformatics

Just came back from the The Microbiome Times Partering Forum, where I met a Phage ACT colleague Frédérique Vieville :) Would definitely recommend this conference to (industrial) people from the field !

Really happy to have been part of the Bacteriophage Therapy Summit! It was great catching up with friends and meeting new people who share the same passion. Phages are gaining momentum—exciting times ahead! Brandon Sharp, Milan Bunata, Frédérique Vieville, Joshua Iszatt, Chris Malajczuk, Frenk Smrekar , Sofia Corte-Real, Miguel Garcia, Olli Pitkänen, Nancy Tawil

[NEW ARTICLE ON OUR TECHNOLOGY]💡 Phage therapy is a promising alternative in the fight against antimicrobial resistance, but ensuring its safety requires high-quality genome annotation. Traditionally, manual annotation has been the gold standard—accurate but slow and resource-intensive. The scientific community has developed great tools—such as Pharokka—to quickly generate annotation results, but none of the current solutions fully match the accuracy of manual genome annotation. Our latest research compares manual annotation (SEA-PHAGES) with the automated rTOOLS (RimeTOOLS) pipeline from Rime Bioinformatics. The results? ✅ Manual annotation still has an edge in structural annotation (gene-calling), but its impact on functional annotation is minimal. ✅ rTOOLS delivers superior functional annotation. ✅ rTOOLS is the first automated pipeline to perform at a level comparable to that of a human phage genome expert. Rime Bioinformatics is bridging the gap between precision and efficiency, ensuring phage therapy advances faster—without compromising on quality. 🔬 Read the full study: https://lnkd.in/gFRrG4FC #PhageTherapy #Genomics #Bioinformatics #AMR #Bacteriophages #Innovation

Ecstatic to welcome Rime Bioinformatics as an Exhibition Partner at our 7th Bacteriophage Therapy Summit! Antoine Culot Guillaume Abriat #bacteriophage #phagetherapy #bioinformatics #bioinformaticstool #boston

📣👨🔬 We have an exciting news to share!  Yes! We are thrilled to announce that we have recently joined PhageEU, a dynamic and growing network dedicated to advancing the field of phage therapy! This membership is a significant step in our journey, as it allows us to collaborate with leading experts and organizations from across Europe. 🇪🇺 By being part of this network, we aim to contribute to innovative research, share knowledge, and drive forward the development of phage-based solutions to fight against AMR. ✊ With this opportunity, we will do our best to make a real impact in the fight against antibiotic resistance and improve healthcare outcomes with phage. 🧬 🔬 #PhageEU #PhageTherapy #Bacteriophages #HealthcareInnovation #AntibioticResistance #ResearchCollaboration  https://lnkd.in/eec5hi3f

🎊 Happy 2025 🎇 Here's something about us.... 👨🔬 The origin of the company’s name is that “Rime” in English is synonymous with “hoarfrost.” It is based on the image of a thin layer of ice separating our clients from the information contained in their genomic data—one that we melt away. ❄️ 🧬 We are here to assist you on your bacteriophage and bioinformatics projects. #Phage #2025 #Bioinformatics

Yesterday, I was at the European Parliament for an inspiring discussion on “The Potential of #Bacteriophages in Fighting #AMR”. Grateful to see policymakers, researchers, and industry working together to tackle one of the greatest health challenges of our time!

Had a wonderful time with the French phage network at the Phages.fr conference this week ! I am excited to be heading next week to Boston and the Phage Futures Congress 2024, to meet the American community =)

[#HLTH] Last but not least! Discover our French companies coming together to showcase their latest innovations in digital health at HLTH Inc. US in Las Vegas, October 20-23.   Millet Innovation develops silicone gels with unique properties (pressure distribution, self-adhesion, skin tissue substitution, etc.) to compensate for certain deficiencies in the human body’s functions or to limit the factors that encourage the development of pathologies. Moona.Health's platform connects patients with qualified sleep therapists via telehealth. It ensures accessible, affordable, and high-quality sleep treatment, addressing the shortage of professionals, fragmented care, and long waitlists. Nova In Silico leverages advanced computational models to revolutionize the design and execution of clinical trials by digitally simulating efficacy on hundreds of thousands of virtual patients, each with a unique physiological makeup. Nova In Silico envisions a future where clinical trials are systematically run digitally first, enabling rapid and ethical advancements in medicine. Rime Bioinformatics specializes in high-performance bioinformatics analysis for bacteriophage research, ensuring the safety and efficacy of phage-based treatments. The company's mission is to support the development of phage therapies as a sustainable alternative to antibiotics. TraceX is a free, open-source eQMS designed for managing the end-to-end creation of medical devices. It is considered an all-in-one solution, as it includes everything needed for collaboration: a task manager, a virtual office, chat functionality, and a wiki. More information about the companies: https://lnkd.in/ev73qpeM Victor Vanbremeersch, Lucie Jolivet, solene grivolat, Julie Pitrat, Guillaume Abriat, Ludmilla Potiron, Nam-Hee LEE, Charlotte Avril, Karine MORYOUSSEF

🚨 Understanding Phage Resistance in Multi-Drug Resistant Enterococci 🚨 While certain phages can lyse some strains of multi-drug resistant (MDR) enterococci, other strains exhibit high levels of resistance, with the underlying mechanisms remaining poorly understood. 🔬 CRISPRi Screen Unveils Genetic Locus Linked to Phage Resistance 🔬 Researchers used a CRISPR interference (CRISPRi) screen to pinpoint a genetic locus on a mobilizable plasmid from Enterococcus faecalis associated with phage resistance. This locus encodes a putative serine recombinase followed by a Type IV restriction enzyme (TIV-RE), which was shown to restrict the replication of phage phi47 in vancomycin-resistant E. faecalis. Key discoveries include: - The identification of a genetic locus that contributes to phage resistance in MDR enterococci. - The role of TIV-RE in restricting phage replication, with phi47 evolving to overcome this defense by acquiring a missense mutation in a TIV-RE inhibitor protein. - The discovery that this inhibitor, named Type IV Restriction Inhibiting Factor A (tifA), binds to and inactivates diverse TIV-REs. 🔍 Implications for Phage Therapy and Resistance Mechanisms 🔍 These findings significantly advance the understanding of phage defense mechanisms in drug-resistant E. faecalis and provide valuable insight into how phages can evolve to overcome antiphage defense systems. This research could inform future strategies for phage therapy and combatting antibiotic resistance. #PhageTherapy #AntibioticResistance #Microbiology #CRISPRI #EnterococcusFaecalis #InfectiousDiseases #Biotechnology #PhageResearch https://lnkd.in/efwWWGR4